Esperion Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ESPR Nasdaq 2836 www.esperion.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Esperion Therapeutics, Inc.

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 - May 26th, 2026 6:00 am
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 14th, 2026 2:30 pm
ESPR Stock Surges 44% in a Month: Here's What You Need to Know - May 14th, 2026 8:44 am
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 - May 13th, 2026 6:00 am
ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal - May 1st, 2026 9:13 am
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal - May 1st, 2026 6:28 am
Esperion to be Acquired by ARCHIMED - May 1st, 2026 5:00 am
Esperion to Report First Quarter 2026 Financial Results on May 7 - Apr 23rd, 2026 6:00 am
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference - Apr 13th, 2026 5:47 pm
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound? - Apr 9th, 2026 9:30 am
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics - Apr 2nd, 2026 2:05 pm
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - Apr 2nd, 2026 2:00 pm
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference - Mar 31st, 2026 6:00 am
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026 - Mar 30th, 2026 6:00 am
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? - Mar 27th, 2026 6:49 am
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines - Mar 20th, 2026 5:59 am
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session - Mar 17th, 2026 6:00 am
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia - Mar 16th, 2026 4:30 am
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference - Mar 15th, 2026 6:03 pm
Esperion Therapeutics Inc (ESPR) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... - Mar 10th, 2026 1:00 pm